Creative Biolabs Released Antibody-drug Conjugate Production Service for Antibody Engineering Research

We Can Expect Much on Creative Biolabs’ Antibody-drug Conjugate Production
Service
With the commitment to developing new generation of pharmaceuticals against
various diseases for both scientific and clinical purposes, Creative Biolabs released
antibody-drug conjugates production service.
Antibody-drug conjugates (ADCs) are composed of antibodies and cytotoxic drugs,
conjugated by chemical linkers. They combine the abilities of mAbs and cytotoxic
drugs, improving the control of drug pharmacokinetics and allowing specific drug
delivery to target cells. A number of ADCs have been researched and entered
clinical trials in recent years. And the successful FDA approval of brentuximab
vedotin (Adcetris ® , SGN-35) and ado-trastuzumab emtansine (Kadcyla ® , T-DM1)
further suggests that ADCs are promising therapeutic agents for oncotherapy.
Based on its ADC platform, Creative Biolabs provides comprehensive custom
services to develop numerous ADC products for every stage of development from
antibody expression to cGMP manufacturing.
Antibody Modification and Conjugation
Creative Biolabs now provides various strategies for antibody modification and
conjugation in antibody drug conjugate (ADC) development. According to the
different reactive sites, the conjugation strategies can be classified into non-specific
conjugation through native residues, site-specific conjugation through genetically
engineered sites and UV cross-linking. Non-specific conjugation technologies are
based on the principle of utilizing reactive side chains of naturally occurring amino
acids, such as lysine and cysteine. Site-specific conjugation can increase the site
specificity of ADC conjugation by altering amino acid sequences to introduce
reactive handles, which includes thio-engineered antibodies (THIOMAB) and
enzymatic modified antibodies. UV cross-linking is also a site-specific conjugation
but does not require genetic engineering or pre-activated scaffolds. It is suitable to
the payloads featuring a UV reactive indole-3-butyric acid (IBA) moiety.
“According to the characteristics of antibodies and special requirements from clients,
we can select the most appropriate conjugation strategy for the ADCs of their
interest”, said Monika, scientific officer of Creative Biolabs
About Creative Biolabs
Creative Biolabs is specialized in providing custom biotechnology and
pharmaceutical products and services that cover the full scope of biotechnology needs
of early antibody drug discovery and development, such as antibody conjugation
service and conjugation antibody.